Insider Buying: Intrexon Corporation (NYSE:XON) Director Buys 5,000 Shares of Stock
Intrexon Corporation (NYSE:XON) Director Dean J. Mitchell bought 5,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were acquired at an average cost of $18.33 per share, for a total transaction of $91,650.00. Following the transaction, the director now directly owns 18,103 shares in the company, valued at approximately $331,827.99. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Intrexon Corporation (NYSE:XON) traded up 5.31% on Friday, hitting $19.65. 2,094,714 shares of the stock were exchanged. The stock’s market cap is $2.35 billion. Intrexon Corporation has a 52-week low of $17.70 and a 52-week high of $32.90. The company’s 50 day moving average is $23.08 and its 200-day moving average is $21.96.
Intrexon Corporation (NYSE:XON) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative return on equity of 19.04% and a negative net margin of 60.63%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.42) earnings per share. Analysts predict that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Insider Buying: Intrexon Corporation (NYSE:XON) Director Buys 5,000 Shares of Stock” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/11/insider-buying-intrexon-corporation-nysexon-director-buys-5000-shares-of-stock.html.
Several large investors have recently modified their holdings of XON. Pacer Advisors Inc. increased its stake in shares of Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Intrexon Corporation during the first quarter valued at $164,000. Federated Investors Inc. PA bought a new stake in shares of Intrexon Corporation during the second quarter valued at $172,000. Cullinan Associates Inc. bought a new stake in shares of Intrexon Corporation during the second quarter valued at $201,000. Finally, John G Ullman & Associates Inc. bought a new stake in shares of Intrexon Corporation during the second quarter valued at $212,000. 84.38% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have commented on XON shares. BidaskClub downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $40.50.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.